You are here

  • Home
  • Archive
  • Volume 7, Issue 5
  • Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV…

Citation Tools

Article menu

Download PDFPDF

XML
Diabetes and endocrinology
Protocol
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Koshizaka M, Ishikawa K, Ishikawa T on behalf of the PRIME-V Study Investigators, et al
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)
BMJ Open 2017;7:e015766. doi: 10.1136/bmjopen-2016-015766